Not Yet Recruiting PHASE1 INTERVENTIONAL 2-arm
NCT06549751
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)
A Phase 1 Study Of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Sponsor: Marker Therapeutics, Inc.
Conditions
Pancreas Cancer
Interventions
MT-601
Updated 1 time since 2024 Last updated: Aug 8, 2024 Started: Sep 30, 2024 Primary completion: Sep 30, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1 clinical study on Pancreas Cancer, this trial is actively recruiting participants. The trial is conducted by Marker Therapeutics, Inc. and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Marker Therapeutics, Inc.
Data source: Marker Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.